Jury rules Qiagen infringed two gene patents

A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

PTAB blocks Qiagen’s bid to invalidate diagnostics patent

20 July 2020 Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.

Medtech

Qiagen and BD settle PCR lawsuit for £53m

9 November 2021 Qiagen will pay Becton, Dickinson $53 million to settle an ongoing patent infringement lawsuit over polymerase chain reaction diagnostics patents.

Big Pharma

Qiagen seeks judgment in COVID-19 wastewater testing suit

7 April 2022 Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.

More on this story

Big Pharma

Qiagen seeks judgment in COVID-19 wastewater testing suit

7 April 2022 Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.

Medtech

Qiagen and BD settle PCR lawsuit for £53m

9 November 2021 Qiagen will pay Becton, Dickinson $53 million to settle an ongoing patent infringement lawsuit over polymerase chain reaction diagnostics patents.

Biotechnology

PTAB blocks Qiagen’s bid to invalidate diagnostics patent

More on this story

Big Pharma

Qiagen seeks judgment in COVID-19 wastewater testing suit

7 April 2022 Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.

Medtech

Qiagen and BD settle PCR lawsuit for £53m

9 November 2021 Qiagen will pay Becton, Dickinson $53 million to settle an ongoing patent infringement lawsuit over polymerase chain reaction diagnostics patents.

Biotechnology

PTAB blocks Qiagen’s bid to invalidate diagnostics patent